Cantor Fitzgerald Initiates Coverage On Sagimet Biosciences with Overweight Rating, Announces Price Target of $10.71

Benzinga · 2d ago
Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Sagimet Biosciences (NASDAQ:SGMT) with a Overweight rating and announces Price Target of $10.71.